Samsung Bioepis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Samsung Bioepis (US): 8 reconciled FDA prescription therapies, $53.2M 2024 CMS Part D & Medicaid spend, and $5,830 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$53.2M
2024 Medicare Part D Spend$12.5M
2024 Medicaid Spend$40.6M
California HCAI SB 17 FilingsSpecialty launch notice ($5,830 intro WAC)